Science

GLP-1 targets beyond obesity, and misusing brain data

Read full article at source ↗

Based on the episode description, not a full transcript. Source evidence retrieved 05/11/2026, 19:31:25 UTC.

Briefings

This podcast episode investigates the dual risks of consumer brain wave detectors selling AI training data without consent, while exploring GLP-1 agonists' potential applications in cognition, cancer, and addiction. Host Jonathan Moens reports on the data harvesting issue, and host Sarah Crespi interviews Yevgeniya Nusinovich and Nora Volkow regarding GLP-1 therapies. The discussion covers the special issue on GLP-1s published in Science.

Key points

• Companies are selling consumer-grade brain wave detectors for sleep and meditation without user consent, exchanging device prices for AI training data.
• GLP-1 agonists are being researched for cognitive improvement, cancer treatment, and addressing addiction to various substances.

Context

Investigative journalist Jonathan Moens reports on the privacy risks of brain wave detectors, while hosts Sarah Crespi and Yevgeniya Nusinovich discuss GLP-1 therapies. Nora Volkow from the NIH provides expert perspective on GLP-1 applications.

Limitations

Evidence covers only the podcast episode content. No additional background on GLP-1 research or brain wave detector market details is supplied beyond the podcast discussion.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 05/11/2026, 20:05:35 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihi7acsjo66ynk54sjemaoio26gwkgjegh6huqwdi54dhinh3tq5a